索拉非尼在肝癌外科综合治疗中的价值

Abstract

Abstract: The HCC (hepatocellular carcinoma,HCC) has high incidence,treatment of intractable,and the prognosis is poor,lt needs combined therapy.The radical treatment including surgical resection,liver transplantation,TACE,radiofrequency,ablation,immunotherapy and so on.In recent years with sorafenib as a representative of the molecular targeted drugs shows significant curative effect in treating HCC.This review aims to collecting the latest related researches about sorafenib in HCC in recent years,and carries on the classified analysis,in order to have a comprehensive understanding to guide its clinical application.

Key words: Target drugs, HCC, Multidiscipline therapy, Sorafenib

CLC Number:

735.7

WANG Wen-tao, ZHANG Peng, YAN Lü-nan. The value of sorafenib in surgical treatment of hepatocellular carcinoma[J]. Surgical Research and New Technique, 2013, 2(4): 229-231.

References

[1]Lau W-Y,Lai E.Hepatocellular carcinoma:current management and recent advances[J].Hepatobiliary Pancreat Dis Int,2008,7(3):237-257.
[2] Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].A Cancer Journal for Clinicians,2005,55(2):74-108.
[3] Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
[4] Alves R,Alves D,Guz B,et al.Advanced hepatocellular carcinoma.Review of targeted molecular drugs[J].Ann Hepatol,2011,10(1):21-27.
[5] Villanueva A,Llovet JM.Targeted therapies for hepatocellular carcinoma[J].Gastroenterology,2011,140(5):1410-1426.
[6] Chung YH,Han G,Yoon JH,et al.Interim analysis of START:Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial[J].Int J Cancer,2012,132(10):2448-2458.
[7] Cheng A-L,Kang Y-K,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised,double-blind,placebo-controlled trial[J].Lancet Oncology,2009,10(1):25-34.
[8] Abou-Alfa GK,Schwartz L,Ricci S,et al.Phase II study of sorafenib in patients with advanced hepatocellular carcinoma[J].J Clin Oncol,2006,24(26):4293-4300.
[9] de Lope CR,Tremosini S,Forner A,et al.Management of HCC[J].J Hepatol,2012,56:S75-S87.
[10] Sergio A,Cristofori C,Cardin R,et al.Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC):the role of angiogenesis and invasiveness.[J].Am J Gastroenterol,2008,103(4):914-921.
[11] Semela D,Dufour JF.Angiogenesis and hepatocellular carcinoma[J].J Hepatol,2004,41(5):864-80.
[12] Kudo M.Current status of molecularly targeted therapy for hepatocellular carcinoma:clinical practice[J].Int J Clin Oncol,2010,15(3):242-255.
[13] Lencioni R,Llovet J,Han G,et al.Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC):phase II,randomized,double-blind SPACE trial[J].J Clin Oncol,2012,30(Suppl 4):154.
[14] Abdel-Rahman O,Elsayed Z.Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma:A Systematic Review of the Literature[J].Dig Dis Sci,2013,58(26):3389-3396.
[15] Choi GH,Shim JH,Kim M-J,et al.Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma:Results of Propensity Score Analyses[J].Radiology,2013,269(2):603-611.
[16] Toso C,Mentha G,Kneteman NM,et al.The place of downstaging for hepatocellular carcinoma[J].J Hepatol,2010,52(6):930-936.
[17] Hubner M,McCormack L,Clavien PA.Surgical therapy of liver tumors:resection vs.ablation[J].Praxis,2005,94(33):1255-1259.
[18] 刘允怡,赖俊雄.肝癌治疗新进展[J].临床外科杂志,2007,15(1):2-7.
[19] L Barbier.Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib[J/OL].http:∥dx:doi.org/10.4061/2011/791013,2011-03-20.
[20] Bathaix F,Marion D,Cuinet M,et al.Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach[J].Gastroentrol Clin Biol,2010,34(4):314-318.
[21] Vagefi PA,Hirose R.Downstaging of hepatocellular carcinoma prior to liver transplant:is there a role for adjuvant sorafenib in locoregional therapy? [J].J Gastrointest Cancer,2010,41(4):217-220.
[22] Finkelstein SD,Marsh W,Demetris AJ,et al.Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma[J].Hepatology,2003,37(4):871-879.
[23] Kudo M.Hepatocellular carcinoma 2009 and beyond:from the surveillance to molecular targeted therapy[J].Oncology,2008,75(Suppl 1):1-12.
[24] Feng YX,Wang T,Deng YZ,et al.Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model[J].Hepatology,2011,53(2):483-492.
[25] 周俭,肖永胜,樊嘉.分子靶向药物对肝癌复发转移防治作用[J].中国实用外科杂志,2012,32(10):860-864.
[26] 荚卫东.根治性肝切除联合索拉非尼治疗肝细胞癌的研究进展[J].世界华人消化杂志,2012,20(22):2019-2023.
[27] 常宗宏,汪泳,吴汉平.肝癌的综合治疗及肿瘤抗血管联合疗法[J].世界华人消化杂志,2012,20(5):385-388.

The value of sorafenib in surgical treatment of hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 13

Recommended Articles

Metrics

Comments

[1]	LIU Pengfei, XU Wen, LIU Kai, YE Chun. Differential diagnosis between atypical hepatic abscess and hepatocellular carcinoma [J]. Surgical Research and New Technique, 2019, 8(3): 187-188.
[2]	LIU Pengfei, XU Wen, LIU Kai, YE Chun. Surgical experience of hepatic cyst connected with bile duct [J]. Surgical Research and New Technique, 2019, 8(2): 118-119.
[3]	LIU Pengfei, XU Wen, LIU Kai, YE Chun. Hyperbilirubinemia caused by hemolysis after blood transfusion in liver cancer surgery: Two case reports [J]. Surgical Research and New Technique, 2019, 8(1): 58-59.
[4]	TANG Zhao-you. Approaches to improvement of survival after surgery for hepatocellular carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 213-215.
[5]	YE Shenglong. Multidisciplinary comprehensive therapy  for primary liver cancer [J]. Surgical Research and New Technique, 2013, 2(4): 216-218.
[6]	ZHAO Ze-ming, Becker Thomas, FAN Yue-zu, Ringe Bastian, Klempnauer Jürgen. Hepatocellular carcinoma (HCC) & liver transplantation (LT) [J]. Surgical Research and New Technique, 2013, 2(4): 219-224.
[7]	WANG Jie. Anti-HBV playing an important role in therapy of hepatocellular carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 225-228.
[8]	ZHAN Wan-guang, ZHANG Bi-xiang. Treatment strategies based on evaluation of staging systems for hepatocellular carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 251-254.
[9]	ZHANG Yao-jun, CHEN Min-shan. Multi-disciplinary treatment for recurrent hepatocellular carcinoma after hepatectomy:current status and prospect [J]. Surgical Research and New Technique, 2013, 2(4): 255-258.
[10]	LI Yun-tong, LUO Shun-feng, LIU Jing-feng. Advances in research on prediction for early postoperative metastasis and recurrence in patients with hepatocellular carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 259-261.
[11]	YANG Fan, ZHANG Qi, CHEN Gui-hua. Cellular immunotherapy of hepatocellar carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 262-266.
[12]	LIU Pengfei, LIU Kai, YE Chun, XU Wen. Causes and surgical treatments of intraoperative massive haemorrhage in operation for primary liver cancer [J]. Surgical Research and New Technique, 2017, 6(3): 152-154.
[13]	LIU Congcong, SHI Baomin. Factors influencing complete response rate of liver cancer after percutaneous radiofrequency ablation [J]. Surgical Research and New Technique, 2020, 9(1): 1-5.